Pathways for Successful AI Adoption in Drug Development

The road to developing new drug treatments is paved with risk. In addition to hefty time and cost considerations, preclinical research doesn’t guarantee success in clinical settings – failure rates hover somewhere in the neighborhood of 90%.

However, digital solutions in drug development have transformative potential when it comes to pharma research and development (R&D).

Download the white paper by VeriSIM Life Chief Scientific Officer Dr. Szczepan Baran and Peter Henstock, Machine Learning & AI Lead at Pfizer, to begin advancing the adoption of AI within your organization – from closing the translational gap to better AI benchmarking and more.

Download the Report